{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:14:24Z","timestamp":1778944464121,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102527","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:01:59Z","timestamp":1771952519000},"page":"102527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk-Adapted Follow-up After Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study With Diagnostic Stewardship Modeling"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4345-9183","authenticated-orcid":false,"given":"Horst Emanuel","family":"Lagos-Beitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Neri-Moguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Augusto","family":"Alcacio-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Tena-Gonz\u00e1lez M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Alonso Castillejos","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0001","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jalm\/jfae130","article-title":"What is diagnostic stewardship?","volume":"10","author":"Claeys","year":"2025","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/tau.2017.12.31","article-title":"MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?","volume":"7","author":"Schoots","year":"2018","journal-title":"Transl Androl Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102527_bib0003","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2022.07.025","article-title":"Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric magnetic resonance imaging (prostate imaging reporting and data system\/likert 3-5) and negative initial biopsy. A mini systematic review","volume":"82","author":"Grivas","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102527_bib0004","first-page":"217","article-title":"Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy","volume":"25","author":"Wang","year":"2023","journal-title":"Asian J Androl"},{"issue":"Supplement_10","key":"10.1016\/j.clgc.2026.102527_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf128.228","article-title":"Negative biopsies in the presence of PI-RADS 4\/5 lesions\u2013do we need a national standardized protocol?","volume":"112","author":"Robinson","year":"2025","journal-title":"BJS"},{"issue":"12","key":"10.1016\/j.clgc.2026.102527_bib0006","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5489\/cuaj.7843","article-title":"A prospective study of cancer detection rates following early repeat imaging and biopsy of PI-RADS 4 and 5 regions of interest exhibiting no clinically significant prostate cancer on prior biopsy","volume":"16","author":"Becher","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"10.1016\/j.clgc.2026.102527_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","article-title":"Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Maggi","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2026.102527_bib0008","doi-asserted-by":"crossref","first-page":"599.e9-13","DOI":"10.1016\/j.urolonc.2020.03.002","article-title":"The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance","volume":"38","author":"Yaguchi","year":"2020","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102527_bib0009","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.juro.2016.06.079","article-title":"Prostate Magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR","volume":"196","author":"Rosenkrantz","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00345-024-05171-2","article-title":"Prevalence and potential predictors of incidental prostate cancer in patients undergoing surgery for benign prostatic obstruction: a retrospective study in the MRI era","volume":"42","author":"Esperto","year":"2024","journal-title":"World J Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102527_bib0011","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/diagnostics14070677","article-title":"Incidental prostate cancer in patients treated for benign prostatic hyperplasia: analysis from a contemporary national dataset","volume":"14","author":"Bologna","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.clgc.2026.102527_bib0012","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/JU.0000000000004159","article-title":"Management and oncologic outcomes of incidental prostate cancer after transurethral resection of the prostate in Denmark","volume":"212","author":"Leni","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.euo.2024.08.009","article-title":"Incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia: a predictive model","volume":"8","author":"Anract","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102527_bib0014","article-title":"Predictive factors of incidental prostate cancer in patients undergoing surgery for presumed benign prostatic hyperplasia: an updated systematic review and meta-analysis","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102527_bib0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.21873\/invivo.11556","article-title":"Early second round targeted biopsy of PI-RADS score 3 or 4 in 256 men with persistent suspicion of prostate cancer","volume":"33","author":"Pepe","year":"2019","journal-title":"In Vivo"},{"issue":"6","key":"10.1016\/j.clgc.2026.102527_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218280","article-title":"Are prostate specific-antigen (PSA) and age associated with the risk of ISUP grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study","volume":"14","author":"Palsdottir","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2017.01.033","article-title":"Improving the Rotterdam European randomized study of screening for prostate cancer risk calculator for initial prostate biopsy by incorporating the 2014 International Society of Urological Pathology gleason grading and cribriform growth","volume":"72","author":"Roobol","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00345-020-03583-4","article-title":"Should Grade Group 1 (GG1) be called cancer?","volume":"40","author":"Labbate","year":"2022","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102527_bib0019","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00330-024-11062-2","article-title":"MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer","volume":"35","author":"Boschheidgen","year":"2025","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102527_bib0020","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2008.20.3422","article-title":"Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach","volume":"28","author":"Gann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102527_bib0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1464-410X.2012.11607.x","article-title":"Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial","volume":"111","author":"Ploussard","year":"2013","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.clgc.2026.102527_bib0022","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00261-018-1481-8","article-title":"Long-distance longitudinal prostate MRI quality assurance: from startup to 12 months","volume":"43","author":"Curci","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/pcan.2016.59","article-title":"Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions","volume":"20","author":"Hendriks","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.clgc.2026.102527_bib0024","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.21037\/tau-20-1151","article-title":"Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions","volume":"10","author":"Eyrich","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41391-024-00840-0","article-title":"Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer","volume":"28","author":"Robinson","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.clgc.2026.102527_bib0026","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00261-021-03377-1","article-title":"Second-opinion reads in prostate MRI: added value of subspecialty interpretation and review at multidisciplinary rounds","volume":"47","author":"Li","year":"2022","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"10.1016\/j.clgc.2026.102527_bib0027","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clgc.2018.10.006","article-title":"Multiparametric magnetic resonance imaging second opinion may reduce the number of unnecessary prostate biopsies: time to improve radiologists' training program?","volume":"17","author":"Luzzago","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102527_bib0028","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00345-023-04365-4","article-title":"Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion?","volume":"41","author":"Stabile","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2026.102527_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.110929","article-title":"Reconciling discordance between PI-RADS 4 lesions and targeted biopsy: early experience of a multidisciplinary quality improvement protocol with PI-RADS 4 subcategorization","volume":"165","author":"Deivasigamani","year":"2023","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102527_bib0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4081\/aiua.2021.2.139","article-title":"mpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: our experience in 950 cases","volume":"93","author":"Pepe","year":"2021","journal-title":"Arch Ital Urol Androl"},{"issue":"2","key":"10.1016\/j.clgc.2026.102527_bib0031","doi-asserted-by":"crossref","first-page":"58.e1","DOI":"10.1016\/j.urolonc.2021.07.010","article-title":"Determining the diagnostic value of PSMA-PET\/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies","volume":"40","author":"Bodar","year":"2022","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102527_bib0032","doi-asserted-by":"crossref","DOI":"10.4081\/aiua.2024.12358","article-title":"Negative biopsy histology in men with PI-RADS score 5: is it useful PSMA PET\/CT evaluation?","volume":"96","author":"Pepe","year":"2024","journal-title":"Arch Ital Urol Androl"},{"issue":"2","key":"10.1016\/j.clgc.2026.102527_bib0033","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00345-022-04243-5","article-title":"Investigating PSMA-PET\/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance","volume":"41","author":"Wong","year":"2023","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102527_bib0034","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.219028","article-title":"Prostate-specific membrane antigen PET in addition to multiparametric prostate MRI triage in the diagnosis of Prostate cancer: the future is avid","volume":"4","author":"Elfatairy","year":"2022","journal-title":"Radiol Imaging Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102527_bib0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bju.16809","article-title":"Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals","volume":"136","author":"Collins","year":"2025","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clgc.2026.102527_bib0036","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00345-017-2135-0","article-title":"Retrospective analysis of the development of PIRADS 3 lesions over time: when is a follow-up MRI reasonable?","volume":"36","author":"Steinkohl","year":"2018","journal-title":"World J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102527_bib0037","doi-asserted-by":"crossref","first-page":"452.e9-16","DOI":"10.1016\/j.urolonc.2022.06.011","article-title":"Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?","volume":"40","author":"Castellani","year":"2022","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102527_bib0038","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/0272989X06290489","article-title":"Increasing the efficiency of Monte Carlo cohort simulations with variance reduction techniques","volume":"26","author":"Shechter","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clgc.2026.102527_bib0039","first-page":"750","article-title":"Monte Carlo simulation and the clinical laboratory","volume":"113","author":"Connelly","year":"1989","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.clgc.2026.102527_bib0040","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/108155899704500614","article-title":"Monte Carlo methods in clinical research: applications in multivariable analysis","volume":"45","author":"Concato","year":"1997","journal-title":"J Invest Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:28:53Z","timestamp":1778941733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000273"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102527","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-Adapted Follow-up After Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study With Diagnostic Stewardship Modeling","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102527"}}